Investors Offered Chance to Lead Beta Bionics Securities Fraud Lawsuit

Rosen Law Firm, an international investor rights law firm, has notified purchasers of Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025, and February 24, 2026, inclusive, of an upcoming lead plaintiff deadline on November 3, 2026. Investors who bought stock during this period are being urged to consider leading a class action lawsuit against the company.

The lawsuit alleges that Beta Bionics made materially false and misleading statements to the market concerning its automated insulin delivery system, the iLet Bionic Pancreas insulin pump. According to the complaint, the U.S. Food and Drug Administration (FDA) had identified numerous serious issues with the device, including dangerously high insulin doses leading to hypoglycemic events.

The complaint details that issues reported to the FDA were significant, numbering in the thousands and including hundreds of life-threatening events requiring substantial medical intervention. It is further alleged that Beta Bionics failed to implement meaningful corrective actions in response to these problems.

Investors who purchased Beta Bionics common stock and incurred losses are encouraged to contact Rosen Law Firm for information on how to participate in the class action. The firm notes that representation can be on a contingency fee basis, meaning no out-of-pocket fees are charged unless a recovery is made.